Immune function of C1q and its modulators CD91 and CD93

Critical Reviews in Immunology

Volumn 25, Issue 4, 2005, Pages 305-330

  Tarr, Joanna ^a   Eggleton, Paul ^a,b  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Apoptosis; C1q; CD91; CD93; Collectins; Phagocytosis

Indexed keywords

CD93 ANTIGEN; COLLAGEN; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; COMPLEMENT CLASSICAL PATHWAY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; GENE DELETION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; APOPTOSIS; COMPLEMENT C1Q; HUMANS; IMMUNITY, NATURAL; MEMBRANE GLYCOPROTEINS; PHAGOCYTOSIS; RECEPTORS, COMPLEMENT;

EID: 30444440869     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.v25.i4.40     Document Type: Review

References (176)

1. Feng X, Tonnesen MG, Peerschke EI, Ghebrehiwet B. Cooperation of C1q receptors and integrins in C1q-mediated endothelial cell adhesion and spreading. J Immunol. 2002;168:2441-8.
2. Ohkuro M, Kobayashi K, Takahashi K, Nagasawa S. Effect of C1q on the processing of immune complexes by human neutrophils. Immunology. 1994;83:507-11.
3. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol. 1997;158:4525-8.
4. Van Schravendijk MR, Dwek RA. Interaction of C1q with DNA. Mol Immunol. 1982;19:1179-87.
5. Volanakis JE, Narkates AJ. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. J Immunol. 1981;126:1820-5.
6. Thielens NM, Tacnet-Delorme P, Arlaud GJ. Interaction of C1q and mannan-binding lectin with viruses. Immunobiology. 2002;205:563-74.
7. Prellner K. C1q binding and complement activation by capsular and cell wall components of S. pneumoniae type XIX. Acta Pathol Microbiol Scand [C]. 1981;89:359-64.
8. Borsos T. Histories and mysteries about C1. Behring Inst Mitt. 1989:1-7.
9. Lepow IH, Naff GB, Todd EW, Pensky J, Hinz CF. Chromatographic resolution of the first component of human complement into three activities. J Exp Med. 1963;117:983-1008.
10. Matsushita M, Endo Y, Fujita T. MASP1 (MBL-associated serine protease 1). Immunobiology. 1998;199:340-7.
11. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, Reid KB, Jensenius JC. A second serine protease associated with mannan-binding lectin that activates complement. Nature. 1997;386:506-10.
12. Schreiber RD, Pangburn MK, Lesavre PH, Muller-Eberhard HJ. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A. 1978;75:3948-52.
13. Lu J, Wiedemann H, Timpl R, Reid KB. Similarity in structure between C1q and the collectins as judged by electron microscopy. Behring Inst Mitt. 1993:6-16.
14. Reid KB, Lowe DM, Porter RR. Isolation and characterization of C1q, a subcomponent of the first component of complement, from human and rabbit sera. Biochem J. 1972;130:749-63.
15. Yonemasu K, Stroud RM. Structural studies on human C1q: non-covalent and covalent subunits. Immunochemistry. 1972;9:545-54.
16. Reid KB. Isolation, by partial pepsin digestion, of the three collagen-like regions present in subcomponent C1q of the first component of human complement. Biochem J. 1976;155:5-17.
17. Brodsky-Doyle B, Leonard KR, Reid KB. Circular-dichroism and electron-microscopy studies of human subcomponent C1q before and after limited proteolysis by pepsin. Biochem J. 1976;159:279-86.
18. Reid KB. Molecular cloning and characterization of the complementary DNA and gene coding for the B-chain of subcomponent C1q of the human complement system. Biochem J. 1985;231:729-35.
19. Sellar GC, Blake DJ, Reid KB. Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent C1q. The complete derived amino acid sequence of human C1q. Biochem J. 1991;274(Pt 2):481-90.
20. Cooper NR. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol. 1985;37:151-216.
21. Reid KB. Chemistry and molecular genetics of C1q. Behring Inst Mitt. 1989:8-19.
22. Ziccardi RJ, Cooper NR. Active disassembly of the first complement component, C-1, by C-1 inactivator. J Immunol. 1979;123:788-92.
23. Ziccardi RJ. A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement. J Immunol. 1982;128:2505-8.
24. Boyd J, Burton DR, Perkins SJ, Villiers CL, Dwek RA, Arlaud GJ. Neutron scattering studies of the isolated C1r2C1s2 subunit of first component of human complement in solution. Proc Natl Acad Sci U S A. 1983;80:3769-73.
25. Tschopp J, Villiger W, Fuchs H, Kilchherr E, Engel J. Assembly of subcomponents C1r and C1s of first component of complement: electron microscopic and ultracentrifugal studies. Proc Natl Acad Sci U S A. 1980;77:7014-8.
26. Arlaud GJ, Gaboriaud C, Thielens NM, Budayova-Spano M, Rossi V, Fontecilla-Camps JC. Structural biology of the C1 complex of complement unveils the mechanisms of its activation and proteolytic activity. Mol Immunol. 2002;39:383-94.
27. Siegel RC, Schumaker VN. Measurement of the association constants of the complexes formed between intact C1q or pepsin-treated C1q stalks and the unactivated or activated C1r2C1s2 tetramers. Mol Immunol. 1983;20:53-66.
28. Strang CJ, Siegel RC, Phillips ML, Poon PH, Schumaker VN. Ultrastructure of the first component of human complement: electron microscopy of the crosslinked complex. Proc Natl Acad Sci U S A. 1982;79:586-90.
29. Burton DR. Immunoglobulin G: functional sites. Mol Immunol. 1985;22:161-206.
30. Paques EP, Huber R, Priess H, Wright JK. Isolation of the globular region of the subcomponent q of the C1 component of complement. Hoppe Seylers Z Physiol Chem. 1979;360:177-83.
31. Schumaker VN, Hanson DC, Kilchherr E, Phillips ML, Poon PH. A molecular mechanism for the activation of the first component of complement by immune complexes. Mol Immunol. 1986;23:557-65.
32. Duncan AR, Winter G. The binding site for C1q on IgG. Nature. 1988;332:738-40.
33. Perkins SJ, Nealis AS, Sutton BJ, Feinstein A. Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation. J Mol Biol 1991;221:1345-66.
34. Arlaud GJ, Gaboriaud C, Thielens NM, Rossi V, Bersch B, Hernandez JF, Fontecilla-Camps JC. Structural biology of C1: dissection of a complex molecular machinery. Immunol Rev. 2001;180:136-45.
35. Kishore U, Ghai R, Greenhough TJ, Shrive AK, Bonifati DM, Gadjeva MG, Waters P, Kojouharova MS, Chakraborty T, Agrawal A. Structural and functional anatomy of the globular domain of complement protein C1q. Immunol Lett. 2004;95:113-28.
36. Rabs U, Martin H, Hitschold T, Golan MD, Heinz HP, Loos M. Isolation and characterization of macrophage-derived C1q and its similarities to serum C1q. Eur J Immunol. 1986;16:1183-6.
37. Muller W, Hanauske-Abel H, Loos M. Biosynthesis of the first component of complement by human and guinea pig peritoneal macrophages: evidence for an independent production of the C1 subunits. J Immunol. 1978;121:1578-84.
38. Ramadori G, Heinz HP, Martin H, Meyer zum Buschenfelde KH, Loos M. Biosynthesis of the subcomponents C1q, C1r and C1s of the first component of complement (C1) by guinea pig hepatocyte primary cultures. Eur J Immunol. 1986;16:1137-41.
39. Tenner AJ, Cooper NR. Stimulation of a human polymorphonuclear leukocyte oxidative response by the CIq subunit of the first complement component. J Immunol. 1982;128:2547-52.
40. Kuna P, Iyer M, Peerschke EI, Kaplan AP, Reid KB, Ghebrehiwet B. Human C1q induces eosinophil migration. Clin Immunol Immunopathol. 1996;81:48-54.
41. Peerschke EI, Ghebrehiwet B. Identification and partial characterization of human platelet C1q binding sites. J Immunol. 1988;141:3505-11.
42. Andrews BS, Shadforth M, Cunningham P, Davis JS IV. Demonstration of a C1q receptor on the surface of human endothelial cells. J Immunol. 1981;127:1075-80.
43. Loos M. Biosynthesis of the collagen-like C1q molecule and its receptor functions for Fc and polyanionic molecules on macrophages. Curr Top Microbiol Immunol. 1983;102:1-56.
44. Tenner AJ, Cooper NR. Identification of types of cells in human peripheral blood that bind C1q. J Immunol. 1981;126:1174-9.
45. Bordin S, Kolb WP, Page RC. C1Q receptors on cultured human gingival fibroblasts: analysis of binding properties. J Immunol. 1983;130:1871-5.
46. Klickstein LB, Barbashov SF, Liu T, Jack RM, Nicholson-Weller A. Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity. 1997;7:345-55.
47. Nepomuceno RR, Henschen-Edman AH, Burgess WH, Tenner AJ. cDNA cloning and primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. Immunity. 1997;6:119-29.
48. Ghebrehiwet B, Silvestri L, McDevitt C. Identification of the Raji cell membrane-derived C1q inhibitor as a receptor for human C1q. Purification and immunochemical characterization. J Exp Med. 1984;160:1375-89.
49. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164:4178-84.
50. Collins C, Tsui FW, Shulman MJ. Differential activation of human and guinea pig complement by pentameric and hexameric IgM. Eur J Immunol. 2002;32:1802-10.
51. Agrawal A, Shrive AK, Greenhough TJ, Volanakis JE. Topology and structure of the C1q-binding site on C-reactive protein. J Immunol. 2001;166:3998-4004.
52. Sorensen IJ, Nielsen EH, Andersen O, Danielsen B, Svehag SE. Binding of complement proteins C1q and C4bp to serum amyloid P component (SAP) in solid contra liquid phase. Scand J Immunol. 1996;44:401-7.
53. Krumdieck R, Hook M, Rosenberg LC, Volanakis JE. The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J Immunol. 1992;149:3695-701.
54. Alvarez-Dominguez C, Carrasco-Marin E, Leyva-Cobian F. Role of complement component C1q in phagocytosis of Listeria monocytogenes by murine macrophage-like cell lines. Infect Immun. 1993;61:3664-72.
55. Alberti S, Marques G, Camprubi S, Merino S, Tomas JM, Vivanco F, Benedi VJ. C1q binding and activation of the complement classical pathway by Klebsiella pneumoniae outer membrane proteins. Infect Immun. 1993;61:852-60.
56. Herbrink P, van den Munckhof HA, Niesters HG, Goessens WH, Stolz E, Quint WG. Solid-phase C1q-directed bacterial capture followed by PCR for detection of Chlamydia trachomatis in clinical specimens. J Clin Microbiol. 1995;33:283-6.
57. Horakova E, Gasser O, Sadallah S, Inal JM, Bourgeois G, Ziekau I, Klimkait T, Schifferli JA. Complement mediates the binding of HIV to erythrocytes. J Immunol. 2004;173:4236-41.
58. Webster S, Glabe C, Rogers J. Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun. 1995;217:869-75.
59. Navratil JS, Watkins SC, Wisnieski JJ, Ahearn JM. The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol. 2001;166:3231-9.
60. Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med. 2000;192:1353-64.
61. Hart SP, Alexander KM, Maccall SM, Dransfield I. C-reactive protein does not opsonize early apoptotic human neutrophils, but binds only membrane-permeable late apoptotic cells and has no effect on their phagocytosis by macrophages. J Inflamm (Lond). 2005;2:5.
62. Kishore U, Sontheimer RD, Sastry KN, Zaner KS, Zappi EG, Hughes GR, Khamashta MA, Strong P, Reid KB, Eggleton P. Release of calreticulin from neutrophils may alter C1q-mediated immune functions. Biochem J. 1997;322(Pt 2):543-50.
63. Dedio J, Jahnen-Dechent W, Bachmann M, Muller-Esterl W. The multiligand-binding protein gC1qR, putative C1q receptor, is a mitochondrial protein. J Immunol. 1998;160:3534-42.
64. Rainard P. Activation of the classical pathway of complement by binding of bovine lactoferrin to unencapsulated Streptococcus agalactiae. Immunology. 1993;79:648-52.
65. Kirschfink M, Blase L, Engelmann S, Schwartz-Albiez R. Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1. J Immunol. 1997;158:1324-31.
66. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol. 1998;8:335-8.
67. Gaboriaud C, Juanhuix J, Gruez A, Lacroix M, Darnault C, Pignol D, Verger D, Fontecilla-Camps JC, Arlaud GJ. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J Biol Chem. 2003;278:46974-82.
68. Eggleton P, Lieu TS, Zappi EG, Sastry K, Coburn J, Zaner KS, Sontheimer RD, Capra JD, Ghebrehiwet B, Tauber AI. Calreticulin is released from activated neutrophils and binds to C1q and mannan-binding protein. Clin Immunol Immunopathol. 1994;72:405-9.
69. Malhotra R. Collectin receptor (C1q receptor): structure and function. Behring Inst Mitt. 1993:254-61.
70. Malhotra R, Willis AC, Jensenius JC, Jackson J, Sim RB. Structure and homology of human C1q receptor (collectin receptor). Immunology. 1993;78:341-8.
71. Ogden CA, deCathelineau A, Hoffmann PR, Bratton D, Ghebrehiwet B, Fadok VA, Henson PM. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med. 2001;194:781-95.
72. Ghiran I, Klickstein LB, Nicholson-Weller A. Calreticulin is at the surface of circulating neutrophils and uses CD59 as an adaptor molecule. J Biol Chem. 2003;278:21024-31.
73. Dickler HB, Kunkel HG. Interaction of aggregated-globulin with B lymphocytes. J Exp Med. 1972;136:191-6.
74. Erdei A, Reid KB. Characterization of C1q-binding material released from the membranes of Raji and U937 cells by limited proteolysis with trypsin. Biochem J. 1988;255:493-9.
75. Malhotra R, Sim RB. Chemical and hydrodynamic characterization of the human leucocyte receptor for complement subcomponent C1q. Biochem J. 1989;262:625-31.
76. Peerschke EI, Reid KB, Ghebrehiwet B. Identification of a novel 33-kDa C1q-binding site on human blood platelets. J Immunol. 1994;152:5896-901.
77. Sim RB, Moestrup SK, Stuart GR, Lynch NJ, Lu J, Schwaeble WJ, Malhotra R. Interaction of C1q and the collectins with the potential receptors calreticulin (cC1qR/collectin receptor) and megalin. Immunobiology. 1998;199:208-24.
78. Stuart GR, Lynch NJ, Day AJ, Schwaeble WJ, Sim RB. The C1q and collectin binding site within C1q receptor (cell surface calreticulin). Immunopharmacology. 1997;38:73-80.
79. McCauliffe DP, Lux FA, Lieu TS, Sanz I, Hanke J, Newkirk MM, Bachinski LL, Itoh Y, Siciliano MJ, Reichlin M, Sontheimer RD, Capra JD. Molecular cloning, expression, and chromosome 19 localization of a human Ro/SS-A autoantigen. J Clin Invest. 1990;85:1379-91.
80. Eggleton P, Reid KB, Kishore U, Sontheimer RD. Clinical relevance of calreticulin in systemic lupus erythematosus. Lupus. 1997;6:564-71.
81. Kovacs H, Campbell ID, Strong P, Johnson S, Ward FJ, Reid KB, Eggleton P. Evidence that C1q binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation. Biochemistry. 1998;37:17865-74.
82. Eggleton P, Ward FJ, Johnson S, Khamashta MA, Hughes GR, Hajela VA, Michalak M, Corbett EF, Staines NA, Reid KB. Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization. Clin Exp Immunol. 2000;120:384-91.
83. Eggleton P, Llewellyn DH. Pathophysiological roles of calreticulin in autoimmune disease. Scand J Immunol. 1999;49:466-73.
84. Hebert DN, Simons JF, Peterson JR, Helenius A. Calnexin, calreticulin, and Bip/Kar2p in protein folding. Cold Spring Harb Symp Quant Biol. 1995;60:405-15.
85. Peterson JR, Ora A, Van PN, Helenius A. Transient, lectin-like association of calreticulin with folding intermediates of cellular and viral glycoproteins. Mol Biol Cell. 1995;6:1173-84.
86. Kasper G, Brown A, Eberl M, Vallar L, Kieffer N, Berry C, Girdwood K, Eggleton P, Quinnell R, Pritchard DI. A calreticulin-like molecule from the human hookworm Necator americanus interacts with C1q and the cytoplasmic signalling domains of some integrins. Parasite Immunol. 2001;23:141-52.
87. Rizvi SM, Mancino L, Thammavongsa V, Cantley RL, Raghavan M. A polypeptide binding conformation of calreticulin is induced by heat shock, calcium depletion, or by deletion of the C-terminal acidic region. Mol Cell. 2004;15:913-23.
88. Johnson S, Michalak M, Opas M, Eggleton P. The ins and outs of calreticulin: from the ER lumen to the extracellular space. Trends Cell Biol. 2001;11:122-9.
89. Llewellyn DH, Johnson S, Eggleton P. Calreticulin comes of age. Trends Cell Biol. 2000;10:399-402.
90. Otabor I, Tyagi S, Beurskens FJ, Ghiran I, Schwab P, Nicholson-Weller A, Klickstein LB. A role for lipid rafts in C1q-triggered O2-generation by human neutrophils. Mol Immunol. 2004;41:185-90.
91. Guan E, Robinson SL, Goodman EB, Tenner AJ. Cell-surface protein identified on phagocytic cells modulates the C1q-mediated enhancement of phagocytosis. J Immunol. 1994;152:4005-16.
92. Ruiz S, Henschen-Edman AH, Nagase H, Tenner AJ. Digestion of C1q collagen-like domain with MMPs-1,-2,-3, and -9 further defines the sequence involved in the stimulation of neutrophil superoxide production. J Leukoc Biol. 1999;66:416-22.
93. Eggleton P, Ghebrehiwet B, Coburn JP, Sastry KN, Zaner KS, Tauber AI. Characterization of the human neutrophil C1q receptor and functional effects of free ligand on activated neutrophils. Blood. 1994;84:1640-9.
94. Goodman EB, Anderson DC, Tenner AJ. C1q triggers neutrophil superoxide production by a unique CD18-dependent mechanism. J Leukoc Biol. 1995;58:168-76.
95. Goodman EB, Tenner AJ. Signal transduction mechanisms of C1q-mediated superoxide production. Evidence for the involvement of temporally distinct staurosporine-insensitive and sensitive pathways. J Immunol. 1992;148:3920-8.
96. McGreal EP, Ikewaki N, Akatsu H, Morgan BP, Gasque P. Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. J Immunol. 2002;168:5222-32.
97. Nepomuceno RR, Ruiz S, Park M, Tenner AJ. C1qRP is a heavily O-glycosylated cell surface protein involved in the regulation of phagocytic activity. J Immunol. 1999;162:3583-9.
98. Nepomuceno RR, Tenner AJ. C1qRP, the C1q receptor that enhances phagocytosis, is detected specifically in human cells of myeloid lineage, endothelial cells, and platelets. J Immunol. 1998;160:1929-35.
99. Guan EN, Burgess WH, Robinson SL, Goodman EB, McTigue KJ, Tenner AJ. Phagocytic cell molecules that bind the collagen-like region of C1q. Involvement in the C1q-mediated enhancement of phagocytosis. J Biol Chem. 1991;266:20345-55.
100. Simmons DL, Satterthwaite AB, Tenen DG, Seed B. Molecular cloning of a cDNA encoding CD34, a sialomucin of human hematopoietic stem cells. J Immunol. 1992;148:267-71.
101. Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, Paradis G, Grupp SA, Sieff CA, Mulligan RC, Johnson RP. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997;3:1337-45.
102. Danet GH, Luongo JL, Butler G, Lu MM, Tenner AJ, Simon MC, Bonnet DA. C1qRp defines a new human stem cell population with hematopoietic and hepatic potential. Proc Natl Acad Sci U S A. 2002;99:10441-5.
103. Graham IL, Gresham HD, Brown EJ. An immobile subset of plasma membrane CD11b/CD18 (Mac-1) is involved in phagocytosis of targets recognized by multiple receptors. J Immunol. 1989;142:2352-8.
104. Steinberger P, Szekeres A, Wille S, Stockl J, Selenko N, Prager E, Staffler G, Madic O, Stockinger H, Knapp W. Identification of human CD93 as the phagocytic C1q receptor (C1qRp) by expression cloning. J Leukoc Biol. 2002;71:133-40.
105. Norsworthy PJ, Fossati-Jimack L, Cortes-Hernandez J, Taylor PR, Bygrave AE, Thompson RD, Nourshargh S, Walport MJ, Botto M. Murine CD93 (C1qRp) contributes to the removal of apoptotic cells in vivo but is not required for C1q-mediated enhancement of phagocytosis. J Immunol. 2004;172:3406-14.
106. Eggleton P, Tenner AJ, Reid KB. C1q receptors. Clin Exp Immunol. 2000;120:406-12.
107. Eggleton P, Reid KB, Tenner AJ. C1q-how many functions? How many receptors? Trends Cell Biol. 1998;8:428-31.
108. Lai AFRF, van Furth R. In vitro synthesis of some complement components (C1q, C3 and C4) by lymphoid tissues and circulating leucocytes in man. Immunology. 1975;28:359-68.
109. Armbrust T, Nordmann B, Kreissig M, Ramadori G. C1Q synthesis by tissue mononuclear phagocytes from normal and from damaged rat liver: up-regulation by dexamethasone, down-regulation by interferon gamma, and lipopolysaccharide. Hepatology. 1997;26:98-106.
110. Vegh Z, Goyarts EC, Rozengarten K, Mazumder A, Ghebrehiwet B. Maturation-dependent expression of C1q binding proteins on the cell surface of human monocyte-derived dendritic cells. Int Immunopharmacol. 2003;3:39-51.
111. Ghebrehiwet B, Peerschke EI. cC1q-R (calreticulin) and gC1q-R/p33: ubiquitously expressed multi-ligand binding cellular proteins involved in inflammation and infection. Mol Immunol. 2004;41:173-83.
112. Leu RW, Zhou AQ, Shannon BJ, Herriott MJ. Inhibitors of C1q biosynthesis suppress activation of murine macrophages for both antibody-independent and antibody-dependent tumor cytotoxicity. J Immunol. 1990;144:2281-6.
113. Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiology. 2002;205:395-406.
114. Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, Botto M, Walport MJ, Fisher JH, Henson PM, Greene KE. Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol. 2002;169:3978-86.
115. Bohlson SS, Zhang M, Ortiz CE, Tenner AJ. CD93 interacts with the PDZ domain-containing adaptor protein GIPC: implications in the modulation of phagocytosis. J Leukoc Biol. 2004;77.
116. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J. 1988;7:4119-27.
117. Kristensen T, Moestrup SK, Gliemann J, Bendtsen L, Sand O, Sottrup-Jensen L. Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor. FEBS Lett. 1990;276:151-5.
118. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol. 2000;1:151-5.
119. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest. 2001;108:779-84.
120. Neels JG, van Den Berg BM, Lookene A, Olivecrona G, Pannekoek H, van Zonneveld AJ. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem. 1999;274:31305-11.
121. Springer TA. An extracellular beta-propeller module predicted in lipoprotein and scavenger receptors, tyrosine kinases, epidermal growth factor precursor, and extracellular matrix components. J Mol Biol. 1998;283:837-62.
122. Gliemann J, Nykjaer A, Petersen CM, Jorgensen KE, Nielsen M, Andreasen PA, Christensen EI, Lookene A, Olivecrona G, Moestrup SK. The multiligand alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha 2MR/LRP). Binding and endocytosis of fluid phase and membrane-associated ligands. Ann N Y Acad Sci. 1994;737:20-38.
123. Moestrup SK, Gliemann J, Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res. 1992;269:375-82.
124. Kounnas MZ, Morris RE, Thompson MR, FitzGerald DJ, Strickland DK, Saelinger CB. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem. 1992;267:12420-3.
125. Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem. 1990;265:17401-4.
126. Kuchenhoff A, Harrach-Ruprecht B, Robenek H. Interaction of apo E-containing lipoproteins with the LDL receptor-related protein LRP. Am J Physiol. 1997;272:C369-82.
127. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 2001;14:303-13.
128. Botto M. Links between complement deficiency and apoptosis. Arthritis Res. 2001;3:207-10.
129. Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC, Savill JS, Henson PM, Botto M, Walport MJ. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med. 2000;192:359-66.
130. Ellgaard L, Riek R, Herrmann T, Guntert P, Braun D, Helenius A, Wuthrich K. NMR structure of the calreticulin P-domain. Proc Natl Acad Sci U S A. 2001;98:3133-8.
131. Michalak M, Corbett EF, Mesaeli N, Nakamura K, Opas M. Calreticulin: one protein, one gene, many functions. Biochem J. 1999;344(Pt 2):281-92.
132. Michalak M, Milner RE, Burns K, Opas M. Calreticulin. Biochem J. 1992;285(Pt 3):681-92.
133. Arosa FA, de Jesus O, Porto G, Carmo AM, de Sousa M. Calreticulin is expressed on the cell surface of activated human peripheral blood T lymphocytes in association with major histocompatibility complex class I molecules. J Biol Chem. 1999;274:16917-22.
134. Vucenik I, Passaniti A, Vitolo MI, Tantivejkul K, Eggleton P, Shamsuddin AM. Anti-angiogenic activity of inositol hexaphosphate (IP6). Carcinogenesis. 2004;25:2115-23.
135. Somersan S, Bhardwaj N. Tethering and tickling: a new role for the phosphatidylserine receptor. J Cell Biol. 2001;155:501-4.
136. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE, Henson PM. By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell. 2003;115:13-23.
137. Nauta AJ, Castellano G, Xu W, Woltman AM, Borrias MC, Daha MR, van Kooten C, Roos A. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol. 2004;173:3044-50.
138. Roos A, Xu W, Castellano G, Nauta AJ, Garred P, Daha MR, van Kooten C. Mini-review: a pivotal role for innate immunity in the clearance of apoptotic cells. Eur J Immunol. 2004;34:921-9.
139. Willnow TE, Orth K, Herz J. Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein. J Biol Chem. 1994;269:15827-32.
140. Storm D, Herz J, Trinder P, Loos M. C1 inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein. J Biol Chem. 1997;272:31043-50.
141. Western E, Denis CV, Bouma BN, Lenting PJ. The alpha-chains of C4b-binding protein mediate complex formation with low density lipoprotein receptor-related protein. J Biol Chem. 2002;277:2511-6.
142. Meilinger M, Gschwentner C, Burger I, Haumer M, Wahrmann M, Szollar L, Nimpf J, Huettinger M. Metabolism of activated complement component C3 is mediated by the low density lipoprotein receptor-related protein/alpha(2)- macroglobulin receptor. J Biol Chem. 1999;274:38091-6.
143. Davis AE III. Biological effects of C1 inhibitor. Drug News Perspect. 2004;17:439-46.
144. Neels JG, Bovenschen N, van Zonneveld AJ, Lenting PJ. Interaction between factor VIII and LDL receptor-related protein. Modulation of coagulation? Trends Cardiovasc Med. 2000;10:8-14.
145. Hahn-Dantona E, Ruiz JF, Bornstein P, Strickland DK. The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism. J Biol Chem. 2001;276:15498-503.
146. Emonard H, Bellon G, Troeberg L, Berton A, Robinet A, Henriet P, Marbaix E, Kirkegaard K, Patthy L, Eeckhout Y, Nagase H, Hornebeck W, Courtoy PJ. Low density lipoprotein receptor-related protein mediates endocytic clearance of pro-MMP-2. TIMP-2 complex through a thrombospondin-independent mechanism. J Biol Chem. 2004;279:54944-51.
147. Emonard H, Bellon G, de Diesbach P, Mettlen M, Hornebeck W, Courtoy PJ. Regulation of matrix metalloproteinase (MMP) activity by the low-density lipoprotein receptor-related protein (LRP). A new function for an "old friend". Biochimie. 2005;87:369-76.
148. Sid B, Sartelet H, Bellon G, El Btaouri H, Rath G, Delorme N, Haye B, Martiny L. Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol. 2004;49:245-58.
149. Wang S, Herndon ME, Ranganathan S, Godyna S, Lawler J, Argraves WS, Liau G. Internalization but not binding of thrombospondin-1 to low density lipoprotein receptor-related protein-1 requires heparan sulfate proteoglycans. J Cell Biochem. 2004;91:766-76.
150. Liu Y, Jones M, Hingtgen CM, Bu G, Laribee N, Tanzi RE, Moir RD, Nath A, He JJ. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med. 2000;6:1380-7.
151. Makarova A, Mikhailenko I, Bugge TH, List K, Lawrence DA, Strickland DK. The low density lipoprotein receptor-related protein modulates protease activity in the brain by mediating the cellular internalization of both neuroserpin and neuroserpin-tissue-type plasminogen activator complexes. J Biol Chem. 2003;278:50250-8.
152. Knauer DJ, Majumdar D, Fong PC, Knauer MF. SERPIN regulation of factor XIa. The novel observation that protease nexin 1 in the presence of heparin is a more potent inhibitor of factor XIa than C1 inhibitor. J Biol Chem. 2000;275:37340-6.
153. Theriault JR, Mambula SS, Sawamura T, Stevenson MA, Calderwood SK. Extracellular HSP70 binding to surface receptors present on antigen presenting cells and endothelial/epithelial cells. FEBS Lett. 2005;579:1951-60.
154. Efferth T, Thelen P, Schulten HG, Bode ME, Granzen B, Beniers AJ, Mertens R, Ringert RH, Gefeller O, Jakse G, Fuzesi L. Differential expression of the multidrug resistance-related protein MRP1 in the histological compartments of nephroblastomas. Int J Oncol. 2001;19:367-71.
155. Pan W, Kasrin AJ, Zankel TC, van Kerkhof P, Terasaki T, Bu G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J Cell Sci. 2004;117:5071-8.
156. Hussain MM. Structural, biochemical and signaling properties of the low-density lipoprotein receptor gene family. Front Biosci. 2001;6:D417-28.
157. Kinoshita A, Shah T, Tangredi MM, Strickland DK, Hyman BT. The intracellular domain of the low density lipoprotein receptor-related protein modulates transactivation mediated by amyloid precursor protein and Fe65. J Biol Chem. 2003;278:41182-8.
158. Miyazaki A, Horiuchi S. [Recent advances in lipoprotein metabolism]. Nippon Rinsho. 1993;51:1954-60.
159. Szanto A, Balasubramaniam S, Roach PD, Nestel PJ. Modulation of the low-density-lipoprotein-receptor-related protein and its relevance to chylomicron-remnant metabolism. Biochem J. 1992;288(Pt 3):791-4.
160. Santo SM, Rensen PC, Goudriaan JR, Bensadoun A, Bovenschen N, Voshol PJ, Havekes LM, van Vlijmen BJ. Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice. J Lipid Res. 2005;46:1097-102.
161. Cavallaro U, Soria MR. Targeting plant toxins to the urokinase and alpha 2-macroglobulin receptors. Semin Cancer Biol. 1995;6:269-78.
162. Walling HW, Raggatt LJ, Irvine DW, Barmina OY, Toledano JE, Goldring MB, Hruska KA, Adkisson HD, Burdge RE, Gatt CJ Jr, Harwood DA, Partridge NC. Impairment of the collagenase-3 endocytotic receptor system in cells from patients with osteoarthritis. Osteoarthritis Cartilage. 2003;11:854-63.
163. Barmina OY, Walling HW, Fiacco GJ, Freije JM, Lopez-Otin C, Jeffrey JJ, Partridge NC. Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization. J Biol Chem. 1999;274:30087-93.
164. Hofer F, Gruenberger M, Kowalski H, Machat H, Huettinger M, Kuechler E, Blass D. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc Natl Acad Sci U S A. 1994;91:1839-42.
165. Tran H, Robinson S, Mikhailenko I, Strickland DK. Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. J Lipid Res. 2003;44:1859-69.
166. Arelin K, Kinoshita A, Whelan CM, Irizarry MC, Rebeck GW, Strickland DK, Hyman BT. LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Res Mol Brain Res. 2002;104:38-46.
167. Bi S, Zhang Y, Wu J, Wang D, Zhao Q. Association between low-density lipoprotein receptor-related protein gene, butyrylcholinesterase gene and Alzheimer's disease in Chinese. Chin Med Sci J. 2001;16:71-5.
168. Ma SL, Ng HK, Baum L, Pang JC, Chiu HF, Woo J, Tang NL, Lam LC. Low-density lipoprotein receptor-related protein 8 (apolipoprotein E receptor 2) gene polymorphisms in Alzheimer's disease. Neurosci Lett. 2002;332:216-8.
169. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest. 2000;106:1159-66.
170. Van Uden E, Sagara Y, Van Uden J, Orlando R, Mallory M, Rockenstein E, Masliah E. A protective role of the low density lipoprotein receptor-related protein against amyloid beta-protein toxicity. J Biol Chem. 2000;275:30525-30.
171. Reddien PW, Horvitz HR. CED-2/CrkII and CED-10/Rac control phagocytosis and cell migration in Caenorhabditis elegans. Nat Cell Biol. 2000;2:131-6.
172. Wu YC, Horvitz HR. C. elegans phagocytosis and cell-migration protein CED-5 is similar to human DOCK180. Nature. 1998;392:501-4.
173. Wu YC, Horvitz HR. The C. elegans cell corpse engulfment gene ced-7 encodes a protein similar to ABC transporters. Cell. 1998;93:951-60.
174. Liu QA, Hengartner MO. Candidate adaptor protein CED-6 promotes the engulfment of apoptotic cells in C. elegans. Cell. 1998;93:961-72.
175. Su HP, Nakada-Tsukui K, Tosello-Trampont AC, Li Y, Bu G, Henson PM, Ravichandran KS. Interaction of CED-6/GULP, an adapter protein involved in engulfment of apoptotic cells with CED-1 and CD91/low density lipoprotein receptor-related protein (LRP). J Biol Chem. 2002;277:11772-9.
176. Arora M, Munoz E, Tenner AJ. Identification of a site on mannan-binding lectin critical for enhancement of phagocytosis. J Biol Chem. 2001;276:43087-94.